|
|
Repligen Corp (NASDAQ: RGEN) |
|
Price: $180.9800
$4.71 
2.672%
|
| Day's High:
| $181.07000732421875
| Week Perf:
| -0.39 %
|
| Day's Low: |
$ 174.01 |
30 Day Perf: |
28.35 % |
| Volume (M): |
790,961 |
52 Wk High: |
$ 188.73 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$141.03 |
| Open: |
$174.23 |
52 Wk Low: |
$100.99 |
|
|
| Market Capitalization (Millions $) |
10,250 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
2,000 |
| Revenues (TTM) (Millions $) |
785 |
| Net Income (TTM) (Millions $) |
42 |
| Cash Flow (TTM) (Millions $) |
-124 |
| Capital Exp. (TTM) (Millions $) |
19 |
Business Description
Repligen Corp is a biotechnology company that specializes in the manufacture and supply of bioprocessing products and technologies.
The company's product portfolio includes Protein A and G ligands, affinity chromatography resins, growth factor supplements for cell culture, and filtration products for virus and gene therapy production.
Repligen Corp was founded in 1981 and is headquartered in Waltham, Massachusetts.
The company's manufacturing facilities are located in Waltham, Massachusetts and Lund, Sweden.
Repligen Corp serves customers in the biopharmaceutical and biotechnology industries worldwide.
The company has a strong focus on the development of novel and innovative technologies that enhance productivity and efficiency in bioprocessing.
This has led to the creation of several proprietary technologies such as the OPUS pre-packed chromatography columns and the ATF (Alternating Tangential Flow) system for high-density cell culture perfusion.
One of Repligen Corp's key strengths is its ability to meet the stringent quality standards of the bioprocessing industry.
The company is ISO 9001:2015 certified and adheres to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) guidelines.
Overall, Repligen Corp is an established player in the bioprocessing industry with a strong track record of innovation and quality.
The company's focus on the development of new products and technologies that increase the efficiency and productivity of bioprocessing is expected to position it for continued growth and success in the future.
Company Address: 41 Seyon Street, Bldg. 1, Suite 100 Waltham 2453 MA
Company Phone Number: 250-0111 Stock Exchange / Ticker: NASDAQ RGEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Contract
Published Sun, Jun 15 2025 10:50 AM UTC
Repligen’s Strategic Acquisition: A New Chapter in Bioprocessing Analytics In a noteworthy development within the biopharmaceutical sector, Repligen Corporation has recently announced the acquisition of an esteemed bioprocessing analytics portfolio from 908 Devices. This acquisition, which encompasses cutting-edge Process Analytical Technology (PAT) devices, is poised to s...
|
| Product Service News
Published Tue, Sep 24 2024 11:30 AM UTC
In an exciting development for the biopharmaceutical industry, Repligen Corporation has inaugurated its Training and Innovation Center (RTIC), marking a significant commitment to elevating customer experience and fostering collaboration within the bioprocessing sector. Situated at the heart of Repligen s operations, the new center is poised to support biopharma and Contract ...
|
| Merger and Acquisition
Published Mon, Jul 29 2024 8:00 PM UTC
In a strategic move poised to redefine the landscape of bioprocessing technology, Repligen Corporation (NASDAQ:RGEN), a leading life sciences company from Waltham, Massachusetts, announced on July 29, 2024, its definitive agreement to acquire the innovative Taiwanese firm Tantti Laboratory Inc. This acquisition underscores Repligen s commitment to advancing its portfoli...
|
| Business Update
Published Mon, Jun 3 2024 1:38 PM UTC
Introducing DurA Cycle Affinity Resin: A Game-Changer in Large-Scale Biologic Manufacturing ST. PAUL, Minn. & WALTHAM, Mass. - Ecolab, a leader in solutions for water, hygiene, and energy technologies, and Repligen Corporation, a renowned life sciences company specializing in bioprocessing technology, have jointly unveiled a groundbreaking product in the field of large-scale...
|
| Financing Agreement
Published Thu, Dec 7 2023 12:30 PM UTC
Repligen Corporation, a leading biotechnology and pharmaceutical company, has recently made a significant announcement regarding a private convertible transaction. On December 6, 2023, Repligen entered into privately negotiated exchange and subscription agreements with specific holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the 2024 Notes) as well as ne...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.73 $ |
| Revenues (TTM) |
13.86 $
|
| Cash Flow (TTM) |
- |
| Cash |
14.31 $
|
| Book Value |
37.29 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
392,551 |
| Net
Income per Employee (TTM) |
20,770 |
| Receivable Turnover Ratio (TTM) |
5.09 |
| Inventory Turnover Ratio (TTM) |
2.08 |
| Asset Turnover Ratio (TTM) |
0.27 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.73 $
|
| Revenues (TTM) |
13.86 $ |
| Cash Flow (TTM) |
- |
| Cash |
14.31 $
|
| Book Value |
37.29 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product |
|
 195.12 % |
of total Revenue |
| Royalty and other revenue |
|
0.04 % |
of total Revenue |
| Member |
|
195.16 % |
of total Revenue |
| |
On February 20 2025 the Repligen provided following guidance
nnRepligen Corporation Unveils Fourth Quarter and Full Year 2024 Financial Resultsnn
nnWALTHAM, Mass., February 20, 2025nn – Repligen Corporation (NASDAQ: RGEN), a prominent player in the life sciences sector specializing in cutting-edge bioprocessing technology, has announced its financial performance for the fourth quarter and the entire year of 2024, concluding the periods ended December 31, 2024. In conjunction with this release, the company also shared its financial outlook for the upcoming year, 2025.
While Repligen has provided an overview of its financial projections for 2025, specific details regarding these estimates have not been disclosed in this announcement. Investors and ma...
|
|
|
1.14%